GLP-1 Market Size Worth USD 133.92 Billion by 2034 | CAGR: 10.9%
The GLP-1 Market size is expected to reach USD 133.92 billion by 2034, according to a new study by Polaris Market Research. The report “GLP-1 Market Share, Size, Trends, Industry Analysis Report: By Route of Administration (Oral and Parenteral), By Type of Molecule, By Active Compound Used, By Type of GLP-1 Agonist Drug, By Target Indication, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a major role in glucose metabolism. It allows insulin release and incorporates glucagon secretion. Therapeutically, GLP-1 receptor agonists are used to treat type 2 diabetes and support weight management. There is a growing use of these therapies into chronic disease management. Beyond type 2 diabetes, they are used to manage conditions such as obesity and cardiovascular risk. GLP-1 receptor agonists are being adopted as multi-targeted agents that align with evolving treatment guidelines as their clinical benefits become more widely recognized. This expanded utility is promoting greater interest among healthcare providers and patients seeking holistic, outcome-driven care solutions.
Request a free sample copy or read the full market insights : GLP-1 Market Report
The continuous innovation led by pharmaceutical companies aims to improve drug delivery, convenience, and patient compliance. Companies are increasingly investing in next-generation formulations and combination therapies. It helps improve metabolic outcomes with fewer side effects and lower dosing frequency. Also, a growing focus on personalized treatment encourages the development of precision-based GLP-1 therapies tailored to patient profiles. These advancements collectively point to a shift in the market toward more personalized and long-term disease control strategies.
GLP-1 Market Report Highlights
- In terms of type of GLP-1 agonist drugs, long-acting GLP-1 agonists led the market in 2025. The dominance is driven by their extended dosing intervals and consistent clinical outcomes.
- By route of administration, the oral GLP-1 segment is anticipated to grow fastest during the forecast period. Increasing preference for needle-free, convenient treatment alternatives drives the growth.
- In 2025, North America led the global market revenue share. High diabetes/obesity rates and advanced healthcare systems support market growth. Rapid uptake of innovative therapies also fueled the expansion.
- Asia Pacific is expected to register the highest growth rate during the forecast period. The growth is fueled by surging prevalence of lifestyle-related metabolic disorders
- A few global key market players include AstraZeneca, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Hanmi Pharmaceutical, Novo Nordisk, Pfizer, Roche, Sanofi, and Tonghua Dongbao Pharmaceutical.
Where is the GLP-1 Market Headed?
The rising preference for convenient treatment formats, particularly oral GLP-1 therapies and digitally supported care delivery, will transform the market. Oral formulations improve treatment accessibility for patients who are reluctant to begin injectable therapies. Telehealth, e-prescriptions, and direct-to-patient delivery models are improving prescription continuity. This trend is expected to support the online pharmacy and retail pharmacy segments, especially in chronic weight management and diabetes care.
Another major market trend is the shift from shortage-led demand distortion toward more normalized branded supply conditions. According to FDA updates in 2025, semaglutide injection shortage conditions have been resolved. The agency also increased scrutiny of unapproved or compounded GLP-1 products. This has important implications for market structure, pricing, patient trust, and channel strategy. Such factors will favor regulated and established supply pathways.
What GLP-1 Market Report Reveals?
- What is the global market size, share, and CAGR for the market through 2034?
- What are the market drivers, opportunities, trends, and restraints of the market growth?
- Who are the key players, and what is their relative position in terms of competitive positioning?
- How are the innovations and product pipelines of different players?
- How does the demand for different types of molecules influence the market landscape?
- How does the market differ in type of molecule, active compound used, type of GLP-1 agonist drug, route of administration, target indication, and geography, and which is the leading application?
- What are the trends in the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa?
Polaris Market Research has segmented the market report on the basis of type of molecule, active compound used, type of GLP-1 agonist drug, route of administration, target indication, and region:
By Type of Molecule Outlook (Revenue, USD Billion, 2021–2034)
- Biologics
- Small Molecules
By Active Compound Used Outlook (Revenue, USD Billion, 2021–2034)
- Dulaglutide
- Liraglutide
- Orforglipron
- Retatrutide
- Semaglutide
- Survodutide
- Tirzepatide
- Other Active Compounds
By Type of GLP-1 Agonist Drugs Outlook (Revenue, USD Billion, 2021–2034)
- Long-acting GLP-1 Agonist
- Short-acting GLP-1 Agonist
By Route of Administration Outlook (Revenue, USD Billion, 2021–2034)
- Oral
- Parenteral
By Target Indication Outlook (Revenue, USD Billion, 2021–2034)
- Alzheimer’s Disease
- Non-Alcoholic Steatohepatitis
- Obesity
- Sleep Apnea
- Type 2 Diabetes
By Regional Outlook (Revenue, USD Billion, 2021–2034)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Malaysia
- South Korea
- Indonesia
- Australia
- Vietnam
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Mexico
- Brazil
- Argentina
- Rest of Latin America
